ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) from a hold rating to a buy rating in a report released on Tuesday morning, Zacks.com reports. They currently have $20.00 price objective on the stock.

According to Zacks, “Astellas Pharma, Inc. is engaged in the research, development, manufacturing and marketing of pharmaceuticals drugs. Products offered by the Company include Prograf applicable for the prevention of rejection in organ transplants, Vesicare for treatment of overactive bladder, Protopic for the treatment of atopic dermatitis in the topical immunomodulator class, Harnal to treat the functional symptoms of benign prostatic hyperplasia (BPH), including weak urinary stream, frequent nighttime urination, and sensation of incomplete emptying of the bladder and Fungard an antifungal agent. Astellas Pharma, Inc. is headquartered in Tokyo, Japan. “

ALPMY has been the topic of a number of other research reports. Morgan Stanley began coverage on shares of ASTELLAS PHARMA/ADR in a research report on Thursday, January 23rd. They set an overweight rating on the stock. ValuEngine cut shares of ASTELLAS PHARMA/ADR from a sell rating to a strong sell rating in a research report on Friday, January 31st.

ALPMY stock opened at $17.25 on Tuesday. ASTELLAS PHARMA/ADR has a twelve month low of $12.77 and a twelve month high of $18.37. The stock has a market capitalization of $32.92 billion, a price-to-earnings ratio of 16.44 and a beta of 0.84. The firm’s fifty day simple moving average is $17.32 and its two-hundred day simple moving average is $15.78.

ASTELLAS PHARMA/ADR Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers XTANDI and Eligard for the treatment of prostate cancer; Betanis/Myrbetriq/BETMIGA for overactive bladder (OAB) treatment; Vesicare forOAB treatment; Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia; VESOMNI for storage symptoms and voiding symptoms associated with benign prostatic hyperplasia; Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, animmunosuppressant; and Funguard/MYCAMINE, a candin-type antifungal agent.

Recommended Story: Profit Margin

Get a free copy of the Zacks research report on ASTELLAS PHARMA/ADR (ALPMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ASTELLAS PHARMA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASTELLAS PHARMA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.